NCT05632354View on ClinicalTrials.gov

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions
Sickle Cell Disease
Interventions
DRUG

Osivelotor

Osivelotor

Trial Locations (8)

22031

Inova Schar Cancer Institute, Fairfax

39110

Mississippi Center for Advanced Medicine, Madison

70112

University Medical Center New Orleans, New Orleans

70808

Our Lady of the Lake Hospital, Inc., Baton Rouge

77030

University of Texas Health Science Center, Houston

100254

Lagos University Teaching Hospital, Lagos

200212

University College Hospital Ibadan, Ibadan

700233

Aminu kano Teaching Hospital, Kano

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05632354 - GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) | Biotech Hunter | Biotech Hunter